Zoryve (roflumilast) vs Bimzelx (bimekizumab-bkzx)
Zoryve (roflumilast) vs Bimzelx (bimekizumab-bkzx)
Zoryve (roflumilast) is a topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis in adults, offering a non-steroidal option for localized application on the skin. Bimzelx (bimekizumab-bkzx), on the other hand, is a systemic biologic medication that inhibits interleukin-17A and interleukin-17F, approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. When deciding between the two, patients should consider factors such as the severity of their psoriasis, preference for topical versus systemic treatment, potential side effects, and any pre-existing health conditions that may affect treatment suitability.
Difference between Zoryve and Bimzelx
Metric | Zoryve (roflumilast) | Bimzelx (bimekizumab-bkzx) |
---|---|---|
Generic name | roflumilast | bimekizumab-bkzx |
Indications | Plaque psoriasis | Plaque psoriasis, Psoriatic arthritis |
Mechanism of action | Phosphodiesterase 4 (PDE4) inhibitor | Interleukin-17A and Interleukin-17F inhibitor |
Brand names | Zoryve | Bimzelx |
Administrative route | Topical | Subcutaneous injection |
Side effects | Diarrhea, headache, nausea, decreased appetite, insomnia, back pain | Upper respiratory tract infections, oral candidiasis, injection site reactions |
Contraindications | Hypersensitivity to roflumilast or any of the ingredients | Hypersensitivity to bimekizumab or any of the ingredients |
Drug class | PDE4 inhibitor | Monoclonal antibody |
Manufacturer | Arcutis Biotherapeutics | UCB, Inc. |
Efficacy
Zoryve (roflumilast) for Psoriasis
Zoryve, with the active ingredient roflumilast, is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of plaque psoriasis, including cases that are moderate to severe. The efficacy of Zoryve in treating psoriasis was demonstrated in clinical trials where patients showed significant improvements in their Psoriasis Area and Severity Index (PASI) scores, a measure commonly used to assess the severity of psoriasis. Participants in these trials experienced a reduction in the thickness, scaling, and redness of plaques, which are characteristic symptoms of the condition.
In the clinical trials, Zoryve was evaluated over a 12-week period, where it was applied topically once daily. The results indicated that a substantial proportion of the patients achieved at least a 75% improvement in their PASI score from baseline. This level of improvement is considered clinically meaningful and suggests that Zoryve can be an effective treatment option for individuals with plaque psoriasis, particularly for those who seek a non-systemic treatment approach.
Bimzelx (bimekizumab-bkzx) for Psoriasis
Bimzelx, which contains the active substance bimekizumab-bkzx, is a monoclonal antibody that targets interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines involved in the inflammatory process of psoriasis. Bimzelx has shown efficacy in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Clinical trials have demonstrated that Bimzelx can lead to significant skin clearance, as measured by PASI scores, and the Dermatology Life Quality Index (DLQI), which assesses the impact of skin disease on the quality of life.
In pivotal phase 3 trials, Bimzelx was administered through subcutaneous injection, and a high percentage of patients achieved PASI 90 and PASI 100 responses, indicating 90% and 100% improvements in PASI scores, respectively. These outcomes were observed as early as week 16 and were maintained through week 52, highlighting the potential of Bimzelx as a long-term treatment option for psoriasis. The sustained efficacy over time suggests that Bimzelx can offer significant relief from the symptoms of psoriasis and improve the quality of life for patients with this chronic skin condition.
Regulatory Agency Approvals
Zoryve
Bimzelx
Access Zoryve or Bimzelx today
If Zoryve or Bimzelx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us